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Abstract: Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory
tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been
developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants
of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B
1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological
manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent
plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory
tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines
that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its
correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs,
and action against emerging viral mutant variants is needed.
Key words: COVID-19, variants, neurological symptoms, drugs, vaccines, neutralizing antibodies, SARS-CoV-2

1. Introduction
Recent infectious viral diseases such as severe acute
respiratory syndrome (SARS) and Ebola disease have
given rise to a major threat to public health, causing
significant global pandemics. Previously known severe
acute respiratory syndrome (SARS) coronavirus (SARSCoV), Middle East respiratory syndrome (MERS)
coronavirus (MERS-CoV), and finally coronavirus disease
2019 (COVID-19) coronavirus SARS-CoV-2 caused
severe respiratory discomfort in the last 20 years. SARSCoV originated in the Guangdong province of China in
2002. This virus spread over five continents, infected
8098 people and caused 774 deaths. MERS-CoV emerged
in the Arabian Peninsula. Then, it was detected in 27
countries and effected 2494 people with 858 deaths in
(He et al., 2020; Khan et al., 2020; Walls et al., 2020). In

December 2019, the novel coronavirus was firstly reported
in Wuhan, Hubei province of China, and globally spread.
The World Health Organization (WHO) has named the
causative virus SARS-CoV-2/2019-nCoV and the related
infected disease as coronavirus disease 2019 (COVID-19).
Although first hopes against the COVID-19 pandemic are
borne out by urgently approved vaccines, many mutant
variants from global phylogenies have been reported.
Moreover, neurological diseases and symptoms have
been reported from COVID-19 patients, so there is a
risk that the pandemic may reach an uncontrollable level.
For instance, E484K mutant virus is estimated to have a
6-fold reduction in sensitivity to immune sera and an 11fold reduction in susceptibility to convalescent sera from
persons vaccinated with Pfizer/BioNTech mRNA vaccine
(Collier et al., 2021).
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In particular, the most updated issue we discuss here
is to focus on considering how emerging mutant strains
of concern will impact vaccine, drug, and monoclonal
therapeutic targets in the long term to contain the
pandemic.
2. Variants of concern (VOC)
Viruses generally have one of the highest mutation rates
of all organisms (Almubaid and Al-Mubaid, 2021). It is
known that the rate of spontaneous mutation occurrence
varies between viruses. The mutation rate in RNA viruses
is higher than in DNA viruses and higher in singlestranded viruses than double-stranded ones. In addition,
the large genome size is correlated to the lower mutation
rate (Sanjuán and Domingo-Calap, 2016). It is known
that coronaviruses mutate rapidly, these mutations occur
especially in the spike protein (S protein) genes. These
mutations might allow the virus to evade the host’s immune
response and adapt to the host environment. Alterations in
the S protein may cause the formation of many variants
with different virulence characteristics, as well (Saha
et al., 2020). A variant that has evidence for association
with increased virulence and transmissibility, decreased
efficacy of available diagnostics, therapeutics, and vaccines
is denominated as a variant of concern (VOC) (World
Health Organization, 2021a). There have been numbers of
SARS-CoV2 variants identified and reported worldwide
recently. Among them, B 1.1.7, B 1.351, P.1, and B.1.617
lineages or VOCs were detected and identified in late
2020. The B 1.1.7, B 1.351, and P.1 lineages were reported
in 149, 102, and 59 countries, respectively as of May 25,
2021. In the same report, the sublineages of B.1.617,
B.1.617.1, B.1.617.2, and B.1.617.3 were reported in 41,
54, and 6 countries, respectively (Figure 1) (World Health
Organization, 2021b). Davies et al. (2021) reported that
B.1.1.7 variant was estimated to have a 43%–90% higher
reproduction number than previous variants (Davies et al.,
2021). B.1.351 variant was forecasted to be 1.50 (95% CI:
1.20–2.13) times more transmissible than earlier available
variants (Pearson et al., 2021). P.1 variant was estimated
to be 2.5 times (Coutinho et al., 2021) and 1.7–2.4 times
(Faria et al., 2021) more transmissible than wild type
variant. B.1.617.2 is evaluated to have at least equivalent
transmissibility to B.1.1.7 according to available data for the
present (Public Health England, 2021). Table summarizes
some of the main characteristics of those lineages.
S protein is responsible for mediation of viral entry
to host cell. Firstly, S protein binds to human ACE2
(angiotensin-converting enzyme 2) receptor via its
receptor-binding domain (RBD). Then, it enzymatically
becomes efficient by human proteases (Hoffmann et al.,
2020a; Shang et al., 2020). Because of this role, S protein
became the main target of COVID-19 vaccines. Notable

spike protein mutations of VOCs are also listed in Table.
This section of the manuscript focuses on especially some
spike protein modifications due to its gene mutations
within VOCs below.
2.1. Main characteristics of B.1.1.7 lineage
B.1.1.7 lineage, variant of concern 202012/01 is a variant
that emerged in the UK in September 2020 and rapidly
spread throughout the world. This lineage contains 23
mutations (14 nonsynonymous mutations, 6 synonymous
mutations, and 3 deletions) in its genome of which eight
mutations occur in S protein (Public Health England,
2020). Some of these mutations may regulate protein’s
function such as N501Y, P681H, and H69/V70 deletion
(Goncalves Cabecinhas et al., 2021). N501Y mutation
found within the RBD in S protein of B.1.1.7 lineage may
increase binding to human ACE2 (Luan et al., 2021).
N501Y is estimated to increase infectivity by 52% (Zhao
et al., 2021). N501Y is found in B.1.351 and P.1 lineages,
as well. P681H mutation is found contiguous to the furin
cleavage site at the S1/S2 in the S protein. Although the
function of P681H is unknown, the cleavage of S1/S2 site
is required for S protein-mediated cell-cell fusion and
entry of the virus into human lung cells (Hoffmann et al.,
2020b; Gómez et al., 2021). Double deletion at positions
69-70 (H69/V70 deletion) in B.1.1.7 variant was associated
to affect the performance of diagnostic PCR assays using
the spike glycoprotein (S) gene as a target1.
2.2. Main characteristics of B.1.351 lineage
B.1.351 lineage was firstly determined in South Africa in
early August 2020 and then spread rapidly, too. It is also
described as a variant of concern which is may be associated
with enhanced transmissibility (Tegally et al., 2020). The
genome of this lineage contains several mutations nine of
which are located in S protein gene. Among them, K417N,
E484K, and N501Y occur in RBD of S protein (Wang et
al., 2021). N501Y enhances ACE2 binding affinity as
described above. In contrast, K417N and E484K decrease
the ACE2-binding affinity by breaking two interfacial salt
bridges which ease RBD binding to ACE2 (Cheng et al.,
2021). The effect of the E484K substitution is not exactly
understood; however, this mutation was associated with
escaping neutralizing antibodies (Francisco et al., 2021;
Xie et al., 2021).
B.1.351 lineage also contains D614G mutation in S
protein gene which refers to an increased binding affinity
for ACE2 that results in enhanced activity of viral entry
(Ozono et al., 2021). There are some reports investigating
whether a variant including D614G mutation may increase
infectivity or transmission of virus or not (Korber et al.,
2020; Engelman and Engelman, 2021; Plante et al., 2021;
Zhou et al., 2021).
https://www.who.int/csr/don/31-december-2020-sars-cov2variants/en [accessed 31.05.2021]
1
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Figure 1. Maps of variants of concern reports as of 25 May (World Health Organization, 2021b).

2.3. Main characteristics of P.1 lineage (alias of B.1.1.28.1)
First reported in Japan and previously known as B.1.1.28.1,
the P1 strain was identified in Brazil as of December 2020.
Preliminary data showed the presence of 17 amino acid
changes (including 10 in the spike protein), 3 deletions,
4 synonym mutations, and 4 nucleotide insertions in the
SARS-CoV-2 P1 strain (Faria et al., 2021). The P.1 strain
contains three important mutations in the spike protein
receptor binding site, namely K417T, E484K, and N501Y
as described above (Dejnirattisai et al., 2021).
It has been reported to have reduced neutralizing
activity against the E484K mutation found in P.1 in persons
previously infected or vaccinated with other strains
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of SARS-CoV-2 (Jangra et al., 2021). The first case of
reinfection with strain P.1 (containing mutations S: E484K,
S: N501Y, and S: K417T) was reported unidentified in a
young immunocompromised woman who was infected
with strain B.1 virus 9 months ago. It has been reported
that nasopharyngeal and pharyngeal samples taken during
reinfection of the patient had higher viral loads (SARSCoV-2 RT-PCR Ct value) than those taken during the
first infection, but the patient had equal and moderate
symptomatic infections during both attacks2.
https://virological.org/t/sars-cov-2-reinfection-by-the-newvariant-of-concern-voc-p-1-in-amazonas-brazil/596 [accessed 20
Jan 2021]
2
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Table. Main characteristics of VOCs (as of 25 May 2021) (World Health Organization, 2021b).
PANGO lineage

B.1.351

B.1.617*

Nextstrain clade

20I/501Y.V1

20H/501Y.V2

20J/501Y.V3

-

GR/501Y.V1

GH/501Y.V2

GR/501Y.V3

G/452R.V3

Other names

VOC-202012/01

VOC-202012/02

VOC-202101/02

-

Location of first detection United Kingdom

South Africa

Brazil / Japan

India

Date of first detection

Early August 2020
D80A, D215G,
241/243del, K417N,
E484K, N501Y,
D614G, A701V

December 2020
L18F, T20N, P26S, D138Y,
R190S, K417T, E484K,
N501Y, D614G H655Y,
T1027I, V1176F

October 2020
L452R, D614G, P681R, ±
(E484Q, Q107H, T19R,
del157/158, T478K,
D950N)

20 September 2020
69/70del, 144del, N501Y,
A570D, D614G, P681H,
T716I, S982A, D1118H

B.1.617 viruses are separated into three lineages (B.1.617.1, B.1.617.2, and B.1.617.3).

Hoffman et al. (2021) reported that mutations in
the S proteins of B.1.1.7, B.1.351, and P.1 variants were
consistent with strong entry into human cells (Hoffmann
et al., 2021). It is of great importance that certain mutations
in the P.1 variant may reduce the ability of vaccine-derived
antibodies or antibodies formed due to previous natural
infection to recognize and neutralize the virus, and thus the
ability of this variant to reinfect individuals (Charkiewicz
et al., 2021). More epidemic research data is needed to
better understand the contagiousness of these strains.
2.4. Main characteristics of B.1.617 lineage
B.1.617 variant, also called the “Indian variant”3, was firstly
determined in India, on 5 October 2020. B.1.617 lineage
was described as a VOC in May 2021. B.1.617.1, B.1.617.2,
and B.1.617.3 are sublineages of this lineage which are
different with their mutations and distribution (World
Health Organization, 2021c). Mutations found in this
variant are in groups L452R, D614G, P681R, ± (E484Q,
Q107H, T19R, del157/158, T478K, D950N) characteristic
mutations on the spike protein (World Health Organization,
2021b). This lineage was first reported as a “double
mutant” due to the presence of two distinct and significant
RBD mutations (E484Q and L452R). E484Q and L452R
mutations together cause an escape from the immune
mechanism. The appearance of the E484K mutation in
this variant has caused immune evasion concerns. Many
of these variants are also temporarily linked to increases in
cases (Boehm et al., 2021).
3. Neurological effects of COVID-19
Neurological symptoms due to COVID-19 disease have
been reported in more than 50% of patients. More than
67,529 patients have been researched in 34 different
countries, including China, France, Italy, South Korea,
https://www.sciencemediacentre.org/expert-reaction-to-cases-ofvariant-b-1-617-the-indian-variant-being-investigated-in-the-uk/
[accessed 31 May 2021]
3

B.1.1.28.1 (P.1)

GISAID clade

Characteristics spike
mutations
*

B.1.1.7

Spain, Sweden, the UK, and the United States (US) to date,
on the neurological effects of COVID-19 (Wildwing and
Holt, 2021). The most common neurological symptoms
are fatigue, dizziness, ataxia, dysphagia, taste and smell
dysfunctions, anomia, chronic headache, confusion,
facial pain, depression-related psychiatric findings,
encephalopathy, nonepileptic and epileptic seizures,
and neuronal episodes of transient paralysis (Meppiel et
al., 2020; Taher et al., 2021). Additionally, a systematic
review also described hemorrhagic strokes and cerebral
venous sinus thrombosis, especially in critically ill patients
with COVID-19. To date, it has been unclear whether
the cerebrovascular manifestations are caused by direct
viral action or indirect mediation by inflammatory
hyperactivation (Fraiman et al., 2020).
Among the clinical indications for imaging studies
for COVID-19, chest computed tomography (CT) and
chest radiography have been performed frequently
since the first discovery of the disease in Wuhan, China.
The cerebrospinal fluid (CSF) analysis, neuroimaging
(MRI and CT), and neurophysiological studies
[electroencephalogram (EEG), electromyography (EMG)
studies, nerve conduction study (NCS)] also reported
neurological effects in COVID-19 patients (Yassin et al.,
2021). COVID-19 virus penetrates cells with the receptors
that are ACE2 and the transmembrane serine protease
2 (TMPRSS2). In our whole body, these receptors are
present in the heart, bladder, pancreas, kidney, nose, and
in small amounts in the eyes and the brain (Dong et al.,
2020). These receptors are particularly abundant in glia,
oligodendrocytes, and astrocytes, which are neuronal
cells belonging to the cerebral cortex, the striatum, the
posterior hypothalamic area, the substantia nigra, and the
brain stem (Chen et al., 2021). COVID-19 can pass the
blood–brain barrier by transcribal and lymphatic route,
axonal and transsynaptic transfer (Figure 2) (Baig et al.,
2020; Zubair et al., 2020). Lewis et al. (2020) reported
that 6% of 304 patients had the COVID-19 virus in their
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Figure 2. COVID-19, which causes hypoxia by targeting the lung epithelium, can also target olfactory epithelium, create cytokine
storm, and cause many neurological symptoms (Pennisi et al., 2020)findings available on its neurological manifestations and
their pathogenic mechanisms have not yet been systematically addressed. A literature search on neurological complications
reported in patients with COVID-19 until June 2020 produced a total of 23 studies. Overall, these papers report that patients may
exhibit a wide range of neurological manifestations, including encephalopathy, encephalitis, seizures, cerebrovascular events,
acute polyneuropathy, headache, hypogeusia, and hyposmia, as well as some non-specific symptoms. Whether these features can
be an indirect and unspecific consequence of the pulmonary disease or a generalized inflammatory state on the CNS remains to
be determined; also, they may rather reflect direct SARS-CoV-2-related neuronal damage. Hematogenous versus transsynaptic
propagation, the role of the angiotensin II converting enzyme receptor-2, the spread across the blood-brain barrier, the impact of
the hyperimmune response (the so-called “cytokine storm”. Abbreviations: ACE2:angiotensin II converting enzyme receptor-2;
BBB: blood–brain barrier; GBS: Guillain-Barré syndrome.

CSF associated with encephalopathies, quadriplegia due
to Guillain–Barré syndrome, multifocal strokes, seizures,
headache, vision loss, and neuromuscular disorders.
The cytokine storm that occurs in COVID-19 patients
damages muscles and the blood–brain barrier and
causes encephalopathies headaches; long-term muscular
sequelae of COVID-19 include sarcopenia and cachexia,
muscle edema and weakness, myositis/rhabdomyolysis,
intramuscular hemorrhage, and myalgia (Figure 2)
(Paliwal et al., 2020). In addition, autoantibodies against
COVID-19 cause damage to endothelial cells, astrocytes,
basal ganglia, hippocampus, and olfactory bulbs (Franke
et al., 2021). Reichard et al. (2020) found signs of
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axonal loss, macrophage infiltration, and perivascular
encephalomyelitis in the brains of COVID-19 patients.
Meppiel et al. reported heterogeneous acute nonvascular
lesions in 14 of 192 COVID-19 patients’ MRI findings
and found pleocytosis with CSF of 18 patients, 2 of
them were encephalitis (Meppiel et al., 2020). Although
there are many hypotheses forward like these studies,
the neurological complications of COVID-19 are not
yet clear according to CSF analysis results, but they may
significantly affect the central nervous system. In a recent
retrospective cohort examination using electronic health
records to compare 6 months of outcomes and the rate of
neurological and psychiatric diagnosis (33.62%), including

ÖZKAN OKTAY et al. / Turk J Biol
stroke, dementia, Parkinson, neuromuscular or muscle
diseases, encephalitis, and Guillain–Barré syndrome,
more modest ratios were observed. Moreover, mental
disorders were higher in 236,379 COVID-19 patients than
in 105,579 patients with influenza and 236,038 patients
with other respiratory viruses (Taquet et al., 2021).
Although seizures are a common manifestation of
acute severe medical or neurological illness, COVID-19
is associated with seizures. In the metaanalysis study by
Kubota et al. (2020), epileptiform discharges were detected
in 20.3% of 308 COVID-19 patients. Seizures and status
epilepticus were detected at a low rate (2.085% in total).
A retrospective multicenter study by Lin et al. (2021)
found electrographic seizures in 19 (9.6%) patients,
including nonconvulsive status epilepticus (NCSE) in 11,
epileptiform abnormalities in 96 (48.7%), clinical seizures
during hospitalization in 197 (44.5%) patients with
COVID-19. Antony and Haneef published a systematic
review about EEG abnormalities were altered mental status
(61.7 %), seizure-like events (31.2 %), and postcardiac
arrest (3.5 %) from a total of 617 patients (median age
was 61.3 years) with COVID-19 (Antony and Haneef,
2020). Lambrecq et al. (2021) reported that 57 patients
underwent brain MRI from 78 COVID-19 patients and
perfusion abnormalities, acute ischemic lesions, multiple
microhemorrhages with white matter-enhancing lesions
detected in 41 COVID-19 patients. The authors found
that EEG abnormalities were common in the frontal
lobe of patients and included focal background slowing,
intermittent discharges, and rhythmic delta activity. In
conclusion, it is difficult to provide precise data on the
short- and long-term neurological effects of the virus due
to the small number of research groups performed with
EEG and the lack of control groups. In the literature, many
studies have detected intact cerebral morphology shown by
CT results in COVID-19 patients. Moreover, Galapoulou
et al., (2020), Dixon et al., (2020) and De Stefano et al.,
(2020) reported that acute necrotizing encephalopathy
and cerebral microbleeds in CT and MRI results can
be reflected in EEG results. In an Italian multicenter
retrospective observational study, 34 (31%) patients
had acute ischemic infarcts, 6 (6%) had intracranial
hemorrhage, 2 had cerebral venous thrombosis, 2 had MS
plaque exacerbation, 2 had nonspecific encephalopathy,
2 had Guillain–Barré syndrome, one had Miller Fisher
syndrome, and one had acute encephalopathy among 108
COVID-19 patients according to BT and MRI findings
(Mahammedi et al., 2020). In another retrospective
study with 59 out of 2820 COVID-19 patients reported
MRI images, and accordingly, 3 (5.1%) had known
white matter lesions from multiple sclerosis, 6 (10.2%)
had acute infarcts, 23 (39.0%) had white matter lesions
of small vessel ischemic disease, 4 (6.8%) had subacute
infarcts, 1 (1.7%) had abnormal basal ganglia signal from

hypoxemia, 4 (6.8%) had chronic infarcts, 2 (3.4%) had
microhemorrhage in association with chronic infarcts, and
2 (3.4%) had microhemorrhage associated with acute or
subacute infarcts (Freeman et al., 2021). The authors also
noted that MRI findings were affected by comorbidities
of hypertension and type 2 diabetes mellitus in seven
COVID-19 patients.
ACE2 and TMPRSS2 receptors are highly present in
the olfactory epithelium but absent in olfactory sensory
neurons. Sustentacular cells in the smelling epithelium
are the main target of COVID-19 (Meunier et al., 2021).
Although the WHO reported the loss of smell and taste
from neurological findings related to COVID-19 disease
on May 4, 2020, whether odor and taste loss can be
diagnostic criteria for COVID-19 has been a matter of
debate4. In a prospective study, 67 patients were reported
to experience smell and taste loss from 94 COVID-19
patients, of whom 3 (4.4%) had taste loss, 30 (44.7%)
had both smell and taste impairment, and 34 (50.7%)
had smell impairment (Salcan et al., 2021). Similarly, an
updated review comprising a large-scale study on 40,000
patients from a total of 104 studies reported that anosmia
is the most widespread symptom in COVID-19 infection
in different societies (Meunier et al., 2021). In a large-scale
study, new approaches based on machine learning were
applied to the visual analogue scale (VAS) results of 777
COVID-19 patients. The results reached an average of
80% accuracy, 82% sensitivity, and 78% specificity when
VAS was used in the diagnosis of COVID-19 disease
(Callejon-Leblic et al., 2021). In a recent metaanalysis
involving 107 studies, anosmia was observed in 12,038 of
32,142 COVID-19 patients (prevalence of 38.2%), whereas
dysgeusia was reported in 11,337 of 30,901 COVID-19
patients all over the world (from 101 studies in total)
with the prevalence of 36.6% (Mutiawati et al., 2021). The
frequency of anosmia and dysgeusia is quite common
in respiratory infections due to COVID-19 compared to
others. As a result, current studies are generally concerned
about the short-term (<6 months) results; however, future
studies are needed to elucidate the long-term (>6 months)
neurological symptoms of COVID-19. Consequently, as
the disease affects mental health and the brain, increase
in need for mental health services and neurological
rehabilitation services should be expected.
4. Current COVID-19 treatments
4.1. Drugs for COVID-19
Corona virus has been effective all over the world for
about 2 years, and studies on vaccines and drugs are
intensely carried out in order to effectively fight the
pandemic. Since viruses are constantly mutating in viral
infections, the development of antiviral drugs for now
Coronavirus disease (COVID-19) (who.int) [Accessed 7 April
2021].
4
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is an RNA-dependent RNA polymerase (RdRps) inhibitor,
and it reduces viral replication with early termination of
RNA transcription and thus improves pulmonary function
by reducing viral load in the lungs (Yurdakök Dikmen et
al., 2020) and therefore was suggested as a therapeutic
agent against SARS-CoV-2. As it was also determined to
be a highly effective agent against MERS-CoV by reducing
the viral loads in mice after 12 days of administration and
therefore supporting regaining the normal pulmonary
functions. A combination of RDV and chloroquine in in
vitro research demonstrated effective inhibition of SARSCoV-2 growth in Vero E6 cells. The USA, Norway, and
France continue clinical studies to evaluate the efficacy of
RDV for COVID-19, it has been used to treat COVID-19
patients in the USA and Singapore. In the USA, RDV
was given intravenously and first subjects of COVID-19
recovered (Gordon et al., 2020; Holshue et al., 2020). Drugrelated randomized controlled trials have been continued.
In in vitro VERO cell culture studies, a combination of RDV
and chloroquine have been shown to be effective against
SARS-CoV-2 (Deshpande and Mali, 2020). A metaanalysis
study reported that RDV may have good impact on clinical
improvement in hospitalized COVID-19 patients (Jiang et
al., 2021). The WHO declared that RDV has little effect on
mortality, mechanical ventilation, viral clearance, time to

and beyond has remained a very important challenge
for the scientific world. FDA supported the therapeutic
efficiency of ribavirin (RBV), favipiravir (FVP), remdesivir
(RDV), penciclovir (PCV), chloroquine, nafamostat, and
nitazoxanide against SARS-CoV-2 strain based on in vitro
trials. Currently, several drugs such as hydroxychloroquine
(HCQ), RBV, FVP, lopinavir/ritonavir (LPV/r), RDV, and
oseltamivir have been suggested as effective treatments for
SARS-CoV-2 (Figure 3) (Kocayiğit et al., 2021). However,
in this coronavirus pandemic, no specific drugs have been
approved for COVID-19 yet.
4.1.1. Nucleoside analogs
Nucleoside analogs, RNA-bound RNA polymerase
enzyme blocking and including human coronaviruses in
a broad spectrum of RNA viruses are adenine or guanine
derivatives which affects the structure of viral RNA. RDV,
FVP, RBV, penciclovir, nitazoxanide, and nafamostat
are among drugs that are being tested in controlled
randomized clinical trials for COVID-19. Some of them
are detailed below.
RDV is an important nucleotide analog originally
developed for the treatment of Ebola virus disease and
also it has antiviral activity against multiple phyllo-,
paramyxo-, pneumo-, and corona viruses (Sheahan et al.,
2017). RDV, which has broad spectrum antiviral activity,
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clinical improvement, and duration of hospitalization due
to COVID-195.
FPV is a heteroaromatic molecule with antiviral activity
carrying carboxy amide, fluorine, and hydroxy groups
and shows fluorescent properties. It is a purine analog
and pyrazine carboxamide derivative antiviral agent.
Originally developed to treat influenza, FPV targets RdRps
and blocks the replication of rhinoviruses. In addition to
influenza, recent studies in the literature report that FPV
acts as a broad-spectrum medication that prevents the
multiplication of flavivirus, rhinovirus, poliovirus, arena
viruses, and filovirus. FPV shows its effect by selectively
and strongly inhibiting RdRp in RNA viruses. Wang et
al. (2020) reported that it has been used as an effective
treatment for COVID-19 patients in their observational
study. In addition to FPV, penciclovir and RBV are effective
in reducing SARS-CoV-2 infection in vitro. In February
2020, a report by Cai et al. (2020) showed a significantly
faster mean time to viral clearance by FVP compared to
LPV/r (4 days vs 11 days, p < 0.001). Similarly, Kocayiğit
et al. observed that the FVP group had a shorter duration
of hospitalization than the LPV/r group (Kocayiğit et al.,
2021). Favipiravir should be used in early stage with quick
diagnosis in selected patients (Deshpande and Mali, 2020).
Another antiviral drug RBV is a synthetic purine
nucleoside analogue having an antiviral activity against
SARS-CoV-2 and against a broad-spectrum of both DNA
and RNA viruses (Graci and Cameron, 2006; Deshpande
and Mali, 2020). RBV can potentially act on numerous
steps of the virus life cycle: inhibition of translation due to
reduction in cellular GTP pools or incorporation as a cap
analogue which inhibits translation; inhibition of genome
or transcript capping, by suppression of GTP synthesis or
direct competition; inhibition of RNA synthesis directly
via active-site binding or reduction of GTP synthesis;
ambiguous incorporation into RNA causing increased
mutation and production of nonviable genomes; or
enhancement of the antiviral immune response, preventing
spread and pathogenesis (Graci and Cameron, 2006). The
effect of RBV against SARSCoV-2 is being investigated
in a clinical trial in Hong Kong. It degrades viral RNA
by inhibiting inosine monophosphate dehydrogenase to
reduce the production of guanosine (Deshpande and Mali,
2020).
PCV, an acyclic guanosine analogue, was developed for
the treatment of various herpesvirus infections in Beecham
Pharmaceuticals Laboratories. Penciclovir-triphosphate
is PCV’s active metabolite and inhibits the replicative
function of the viral DNA polymerase competitively.
Unlike acyclovir, penciclovir is not considered a DNA
World Health Organization (2021). Therapeutics and COVID-19:
living guideline, 31 March 2021 [online]. Website https://apps.who.
int/iris/handle/10665/340374 [accessed 08.04.2021].
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chain terminator due to the presence of the 3′-OH group
in its structure. Penciclovir has range spectrum antiviral
activity against VZV, HSV, and EBV (Pastuch-Gawołek
et al., 2019). Yin et al. also reported that FPV, RBV, and
penciclovir are inhibitors of the COVID-19 RdRp, an
essential enzyme for the viral replication (Yin et al., 2020).
Nitazoxanide (NTZ) is a range spectrum antiparasitic
and antiviral medicine used for the treatment of various
protozoal, helminthic, and viral infections (White Jr.,
2004; Rossignol, 2014). NTZ is a thiazolide derivative with
antiinfective effect and it inhibits replication of influenza
viruses, including neuraminidase inhibitor-resistant
strains, blocking the maturation of viral hemagglutin at the
posttranslational level. In cell culture research, NTZ acts
synergistically with neuraminidase inhibitors (Haffizulla
et al., 2014). Therefore, new protocols and therapeutic
approaches with combinations of nitazoxanide/oseltamivir
(Rossignol, 2014), nitazoxanide/hydroxychloroquine
(Haffizulla et al., 2014), and nitazoxanide/azithromycin
(Kelleni, 2020) have been clinically tested against
COVID-19.
Hydroxychloroquine (HCQ) is classified within
the 4-aminoquinoline drug families. Chloroquine, an
antimalarial drug, has been determined to be beneficial
against COVID-19. It was used for the treatment of
COVID-19 patients. It prevents the entry of the virus by
changing the structural configuration of cell receptors
and binding to the cellular receptors competitively. It can
alter the glycosylation of ACE2 cellular receptors required
for SARS-CoV-2 entry into the cell. In other words, this
drug can also reduce the synthesis of sialic acid receptors
to prevent SARS-CoV-2 from binding to host cells
(Frediansyah et al., 2021). However, the WHO reported
that hydroxychloroquine did not reduce duration of
mechanical ventilation and mortality. In addition, taking
hydroxychloroquine to treat COVID-19 may increase the
risk of heart rhythm problems, blood and lymph disorders,
liver problems, and kidney injury6.
In addition to the drugs mentioned above, the FDA
has approved the transcription inhibitors (NtRTIs) such
as tenofovir alafenamide, tenofovir, disoproxil, adefovir,
abacavir, didanosine, and ganciclovir. These antiviral
drugs with similar structural properties with RDV and/
or RBV may make them possible antiviral drugs against
COVID-19. Additionally, some other transcriptase
inhibitors like NRTIs (lamivudine, zidovudine, stavudine,
zalcitabine, emtricitabine, and azvudine) and NNRTIs
(delavirdine, rilpivirine, nevirapine, and efavirenz) have
been approved by the FDA (Lamprou, 2020).
Currently, 5316 randomized controlled clinical trials
are being conducted for COVID-196. In the randomized
controlled clinic studies for COVID-19, there are no
https://clinicaltrials.gov/ [accessed 10.04.2021]
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specific antiviral agents proven across the board reliability
and efficacy yet. However, in order to develop an effective
treatment model, the effects of existing antiviral drugs on
COVID-19 are being investigated. In the global pandemic
process, antivirals such as RDV, FPV, HCQ, and RBV have
attracted more attention in the treatment of COVID-19
patients. Especially, RBV has a versatile antiviral effect.
RDV has been approved by FDA for treating COVID-19.
FPV has been approved in China, Russia, and India for
COVID-19, and it is known that the drug reduces the
treatment time from 11 days to 4 days (Cai et al., 2020; Yin
et al., 2020).
Antiviral drugs applied in a short time following
the onset of symptoms can reduce viral load and
contagiousness, especially if drugs that have proven to have
antiviral effects, such as RBV that has a versatile antiviral
effect, FPV that was developed to treat influenza, and RDV
that was developed for the treatment of Ebola virus, are
used at an early stage. It has been reported in clinical trials
that they provide an effective treatment. However, antiviral
drugs known in clinical trials are not at the desired level
on mortality, mechanical ventilation, viral clearance, and
duration of hospitalization due to COVID-19.
Although the past strategy in combating antimicrobial
pathogens is particularly on target pathogen genes and
proteins, viral genes are exposed to rapid mutation and
show resistance to drugs due to their intrinsic nature.
When antiviral drugs are not administered in the
appropriate replication period, they cause failure and often
resistance development; therefore, drugs affecting the host
become more prominent in the clinic trials for COVID-19.
Especially in the selection of antiviral drugs, there may
be several benefits of targeting host factors such as much
lower DNA polymerase mutation rates than those of RNA
and the ability to control cytokine storm and have a wider
antivirus spectrum of targeted host factors. Therefore,
targeting host factors can be a plausible approach for
developing COVID-19 therapeutics or other emerging
viruses in the future (Cai et al., 2020).
Consequently, treatment protocols in the world
are constantly updated with the results of controlled
randomized clinical trials. Individualized medicine is an
important treatment approach since there is no uniform
drug application in treatment due to individual differences
such as changing phenotype, other chronic diseases and
also in advanced stages of the disease, combinations of
viral drugs are tried to create synergistic effect.
4.2. Currently used COVID-19 vaccines and their
efficiency
There have been more than 200 COVID-19 vaccine
candidates under development since December 2020.
A minimum of 52 candidate vaccines are in the human
trial phase and 18 vaccines are under efficiency trials.

350

When developing a vaccine for COVID-19, three main
approaches were taken: the whole virus, parts of the
virus targeting the immune system, and the viral gene. In
summary, the vaccine types currently being studied on
COVID-19 are inactivated, live-attenuated, viral vector,
subunit, and nucleic acid vaccines. Some COVID-19
vaccines have been developed using an approach that is
not live virus vaccines. The material contains messenger
RNA (mRNA) and viral proteins that do not interfere with
human DNA7.
Currently, there are five FDA- and EMA-approved
vaccines (Figure 4); AstraZeneca (ChAdOx1 nCoV-19)
and Gamaleya developed adenovirus-expressing spike
vaccine; Pfizer/BioNTech (bnt162b2 mRNA vaccine) and
Moderna (mRNA-1273 vaccine) developed RNA vaccines
The World Health Organization (2021). Safety of COVID-19
Vaccines [online]. Website https://www.who.int/news-room/featurestories/detail/safety-of-covid-19-vaccines [Accessed 7 April 2021].
7
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expressing the spike glycoprotein; Sinopharm and Sinovac
developed an inactivated virus vaccine with alum as an
adjuvant (Kim et al., 2021). Pfizer/BioNTech, Gamaleya,
Moderna, Sinopharm, and AstraZeneca have respectively
reported 95%, 92%, 94.5%, 79%, and 70% vaccine efficacy
(Polack et al., 2020). Sinovac (owned by the Chinese
company) announced vaccine efficacies ranging from
50% to 91% (for the same product) for many countries
participating in the efficacy trials, but the full data has not
yet been published as it is still under peer review (Voysey
et al., 2021)8. Although the safety studies of vaccines will
continue until the end of the application all over the world,
the main question currently in mind is whether these
vaccines will provide the same reliability in patients with
chronic diseases or under various treatments. Waissengrin
et al. (2021) reported that the Pfizer/BioNTech vaccine was
offered to 170 patients (cancer and different comorbidities)
treated with immune checkpoint inhibitors. Of these, 137
(81%) patients received the first dose of vaccine, of whom
134 (98%) received the second dose. Three people died
after the first dose. A very large-scale clinical trial showed
that COVID-19 vaccine Moderna was 90.9% effective in
participants at risk of severe illness, including those with
heart disease, chronic lung disease, obesity, diabetes, liver
disease, or HIV infection. High efficacy in this vaccine was
also maintained across racial, gender, and ethnic groups
(Baden et al., 2021). However, chronic and autoimmune
diseases can also be triggered by vaccines. Immune
mechanisms such as antigen presentation, antiidiotypic
status, cytokine production, polyclonal activation of B cells,
and epitope dissemination play a role in both autoreactivity
and antiinfectious immune response. Individuals under
immunosuppressive therapy or those diagnosed with an
immunocompromising condition were generally excluded
in approved COVID-19 vaccine trials (Polack et al., 2020;
Logunov et al., 2021). There are not enough reports to
discuss the efficiency of approved vaccination on chronic,
other infectious and autoimmune diseases. There are some
important questions to ask regarding individuals with
such diseases:
• Could vaccines have serious side effects on these
patients?
• Will vaccines be harmful or beneficial, especially
in combination with immunosuppressive, chemo,
and other therapies?
• Does the vaccine trigger diseases in those with low
immunity and latent autoimmune condition?
Careful attention should be paid to vaccines in
individuals with chronic diseases and pharmacoepidemiological studies are needed for each vaccine
delivery system urgently. Especially special prospective
COVID-19 vaccine trials involving patients with advanced
stage kidney, liver, biliary, intestinal, and comorbid disease,

and their transplant recipients are urgently needed and
likely to emerge soon.
4.3. Neutralizing antibody therapy
The degree and duration of the protection provided by
the immune response that develops in those exposed to
SARS-CoV-2 or those who have had an infection is still
one of the controversial issues. One of the most important
branches of the immune response in this type of infection
is the development of antibodies that recognize the
virus. Antibodies that block binding to the Angiotensin
Converting Enzyme-2 (ACE-2) receptor in the host cell
membrane are antibodies that recognize and bind to the
spike protein of the virus (Oral et al., 2002; Gattinger
et al., 2021). Monoclonal antibodies come first among
neutralizing antibodies. Other important mechanisms
in neutralizing the virus’s binding ability to the receptors
such as transmembrane protease serine 2 (TMPRSS2),
CD147, and CD26, and to directly kill the virus in cultures
or in vivo models (Radzikowska et al., 2020; Gattinger et
al., 2021).
The high-tech approach is to manipulate antibodyproducing B cells obtained from the blood of people with
COVID-19. The most important of these are monoclonal
antibodies (MoAb) (Hurt and Wheatley, 2021). The
production of MoAb is based on the principle that each B
cell produces a unique antibody. The clone of a B cell that
produces quality antibodies (for example, which binds to
the antigen with high affinity) can be expanded and used
by producing antibodies specific to a single antigenic
determinant (epitope) called MoAb. These antibodies can
be cloned from the B cell repertoires of healed patients or
can be produced in vitro by genetic engineering (Beigel,
2018). MoAbs against viruses can be classified in two
main groups according to their targeted location: Those
targeting the receptor structure, or inhibit virus binding
or entry of the host virus; antibiotics with virus replication
and transcription (Owji et al., 2020).
Due to the homology between SARS-CoV and SARSCoV-2, it was initially expected that the SARS-CoV
antibodies would show SARS-CoV-2 cross-reactivity.
However, there are still contradictions about this because
unlike SARS-CoV, there are some highly protected regions
in SARS-CoV-2. For example, the C-terminal part of the
SARS-CoV-2 RBD region is quite different from that of
SARS-CoV. In addition, S1 and S2 subunits not found
in SARS-CoV, in SARS-CoV-2, these units are the furin
cleavage site. These differences do not affect the ability of
the virus to interact with the ACE2 receptor, although there
are differences in the ability of the antibodies developed to
neutralize the virus (Tian et al., 2020; Yuan et al., 2020).
As a matter of fact, the computational-based analysis of
the epitopes of the two viruses showed that 85.3% of the
epitopes belonging to the SARS-CoV-2 spike were different
from those of SARS-CoV (Zheng and Song, 2020). To
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date, studies have shown that only a few (F6G19, CR3022,
and 47D11) of about 25 different monoclonal antibodies
developed against SARS-CoV can neutralize both SARSCoV and SARS-CoV-2 (Owji et al., 2020). For this reason,
research on neutralizing antibodies specific to SARSCoV-2 is also ongoing. In one of these, it has been shown
that the developed SARS-CoV-2 RBD-specific monoclonal
antibodies have a very strong neutralizing property (Ju et
al., 2020). However, it has been demonstrated that these
antibodies do not show cross-reactivity with SARS-CoV
and MERS-CoV. Again, it has been shown that the use
of cocktails of MoAbs that have the ability to specifically
bind to different epitopes in RBD can be more effective in
neutralizing SARS-CoV-2 as well as providing protection
against escape mutants (Wu et al., 2020). Antibodies also
can destroy infected cells, which can change the structure
of a protein or through the effector functions required for
viral entry. Various antibodies against the spike protein
have been developed to block the binding of the receptor to
the host cell membrane8 (Wong, 2020). Anti-SARS-CoV-2
antibodies will bind virus and free from infection with the
hope of effectively detecting a force sufficient to inactivate
were isolated from large patient population (Twomey et
al., 2020). Antibody cocktails, expanding the potential
neutralization, can provide protection against future
mutations in the virus’s spike protein can target different
epitopes. These cocktails were used for pneumonia, and
they showed an activity to decrease the viral load in in
vitro as well as in animal models of injury (Hansen et al.,
2020; Regeneron, 2021).
MoAb on cells and animals in preclinical studies in early
2020 shows promise against COVID-19. Last September,
the first results of these studies came out and several
monoclonal antibodies have since received emergency use
from the FDA (U.S. Food and Drug Administration, 2020).
Various antibody products have been developed to
treat problems caused by cytokine storm and COVID-19
pneumonias. These treatments, IL-6 (Levilimab)
(NCT04397562), TLR4 (EB05) (NCT04401475),
CXCL10 (EB06) and angiopoietin-2 (Ang2) (LY3127804)
(NCT04342897) comprise targeting. Type-I and typeIII interferon or IL-6R targeting TLR4 controls and
suppresses the proinflammatory response in cytokine
storm in patients (Sallenave and Guillot, 2020).
According to published studies evaluating the efficacy
and safety of the use of interferon β-1a (IFN β-1a) in the
treatment of COVID-19, interferon β-1a at a dose of 44
µg was administered subcutaneously to patients in certain
sequential processes. Significantly, it reduced mortality
and hospital stay in early application. The use of interferon
https://investor.lilly.com/news-releases/news-release-details/
lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda
[accessed 31.05.2021]
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β-1a in combination in the treatment of COVID-19 should
be supported (Dastan et al., 2020; Davoudi-Monfared et
al., 2020).
In addition, the bradykinin storm is a subspecies of
the kallikrein-kinin system. It multiplies in the plasma
as a result of the division of cells produced in the liver by
means of proteolytic enzymes. ACE has a higher affinity
for bradykinin than angiotensin I. In cases where ACE is
low, bradykinin is preserved. Due to decreased ACE gene
expression in COVID-19 patients, there will be increases
in bradykinin receptors and enzymes (Van de Veerdonk et
al., 2020). Bradykinin receptor antagonists are of potential
interest, as bradykinin suppresses interferon production,
thereby increasing cellular inflammation. Therapeutics
trying to correct the imbalance in the pathway of
angiotensin and kallikrein products are promising areas of
research in COVID-19 (Roche and Roche, 2020).
First of all, these antibodies are thought to be more
effective than many other drugs because they originate
from the blood of people who have had COVID-19 and
are obtained by selecting the most effective ones. They
can be produced very quickly compared to other drugs
and vaccines. As soon as they are administered, they can
provide effective protection against infection, but their
effectiveness decreases over weeks or months due to the
certain half-life of antibodies. There are no big differences
in effect in children and the elderly. In addition, they are
effective in people with weak immune systems where some
vaccines cannot be administered or an effective immune
response cannot be established with vaccines. Production
of monoclonal antibodies is more complex and expensive
than other types of drugs. Therefore, they are the most
expensive and hardest-to-reach drugs in the world.
A disadvantage of the MOAB is that they can lose their
impressive efficacy against new variants. Mutated variants
escape antibodies produced in those previously infected
with COVID-19. Researchers are developing cocktails of
monoclonal antibodies to overcome the resistance of these
new variants.
5. Conclusion
In conclusion, the COVID-19 epidemic has been on the
agenda of the world since the day it caused a global health
problem. Scientists and health organizations are making
great efforts to control the epidemic and take therapeutic/
preventive measures. In this study, we presented up-to-date
information, especially in terms of variants, neurological
symptoms, drugs, vaccines, and neutralizing antibodies.
Treatment and prophylaxis studies continue rapidly all
over the world.
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